In the United States, more than 40% of cancer patients develop brain metastasis. The median survival for untreated patients is 1 to 2 months, which may be extended to 6 months with conventional radiotherapy and chemotherapy. The growth and survival of metastasis depend on the interaction of tumor cells with host factors in the organ microenvironment. Brain metastases are surrounded and infiltrated by activated astrocytes and are highly resistant to chemotherapy. We report here that coculture of human breast cancer cells or lung cancer cells with murine astrocytes (but not murine fibroblasts) led to the up-regulation of survival genes, including GSTA5, BCL2L1, and TWIST1, in the tumor cells. The degree of up-regulation directly correlated wi...
Brain metastases are highly resistant to chemotherapy. Metastatic tumor cells are known to exploit t...
Despite advances in cancer treatments, cancer is still ranked the second leading cause of death. Can...
Abstract Brain metastases remain a significant challenge in the treatment of breast cancer patients ...
In the United States, more than 40% of cancer patients develop brain metastasis. The median survival...
In the United States, more than 40% of cancer patients develop brain metastasis. The median survival...
Brain metastasis is resistant to chemotherapy while the leaky blood-brain-barrier in brain metastasi...
The microenvironment has emerged as a promising source of novel therapeutic applications in experime...
Brain metastasis, the secondary growth of malignant cells within the central nervous system (CNS), e...
AbstractBrain metastases are highly resistant to chemotherapy. Metastatic tumor cells are known to e...
Primary brain neoplasms and metastases to the brain are generally resistant to systemic chemotherapy...
Background: Although several studies suggest that stromal fibroblasts mediate treatment resistance i...
Currently, survival of breast cancer patients with brain metastasis ranges from 2 to 16 months. In e...
Malignant primary brain tumors are characterized by a short median survival and an almost 100% tumor...
Current research is continually implicating the importance of astrocytes as active participants in n...
Tumor vasculatures and hypoxia are critical tumor micro-environmental factors associated with tumor ...
Brain metastases are highly resistant to chemotherapy. Metastatic tumor cells are known to exploit t...
Despite advances in cancer treatments, cancer is still ranked the second leading cause of death. Can...
Abstract Brain metastases remain a significant challenge in the treatment of breast cancer patients ...
In the United States, more than 40% of cancer patients develop brain metastasis. The median survival...
In the United States, more than 40% of cancer patients develop brain metastasis. The median survival...
Brain metastasis is resistant to chemotherapy while the leaky blood-brain-barrier in brain metastasi...
The microenvironment has emerged as a promising source of novel therapeutic applications in experime...
Brain metastasis, the secondary growth of malignant cells within the central nervous system (CNS), e...
AbstractBrain metastases are highly resistant to chemotherapy. Metastatic tumor cells are known to e...
Primary brain neoplasms and metastases to the brain are generally resistant to systemic chemotherapy...
Background: Although several studies suggest that stromal fibroblasts mediate treatment resistance i...
Currently, survival of breast cancer patients with brain metastasis ranges from 2 to 16 months. In e...
Malignant primary brain tumors are characterized by a short median survival and an almost 100% tumor...
Current research is continually implicating the importance of astrocytes as active participants in n...
Tumor vasculatures and hypoxia are critical tumor micro-environmental factors associated with tumor ...
Brain metastases are highly resistant to chemotherapy. Metastatic tumor cells are known to exploit t...
Despite advances in cancer treatments, cancer is still ranked the second leading cause of death. Can...
Abstract Brain metastases remain a significant challenge in the treatment of breast cancer patients ...